Life Sciences SOW: Why It’s a Workforce Problem

Why Life Sciences SOW Is a Workforce Strategy Problem, Not Just a Procurement One

Life sciences organisations have always outsourced complex work. CROs run clinical trials. CDMOs manufacture product. FSPs embed specialists into delivery teams. The scale of this outsourcing is now enormous. Fortune Business Insights valued the global CDMO market at $255 billion in 2025, with growth projected to $580 billion by 2034.

But most procurement systems were built for a different kind of work. They track hours, headcount, and day rates. They do not track milestones, deliverable sign-off, or bid compliance. Apply that to CRO and CDMO spend, and you get blind spots. Spend goes untracked. Performance goes unmeasured. Compliance risk builds quietly in the background.

This is why SOW management has become a strategic issue, not just a procurement efficiency exercise.

SOW Now Accounts for a Significant Share of Extended Workforce Spend

According to Staffing Industry Analysts’ Workforce Solutions Buyer Survey for 2025, SOW now accounts for 39% of all MSP spend. That is the highest proportion ever recorded. SIA calls SOW management a strategic imperative to remain competitive in an evolving workforce solutions landscape.

That shift is especially clear in life sciences. The sector relies on outcome-based partnerships with CROs, CDMOs, and FSPs. A growing share of workforce activity sits under deliverables-based contracts, not time-and-materials ones. The people executing those contracts are not internal staff. They are not straightforward contract workers either. They are embedded, highly regulated, and deeply specialist.

Generic tools were not built for that.

Where Life Sciences SOW Gets Complicated

A CRO embedded in a sponsor’s extended workforce is not like an IT consultancy or a marketing agency. Its staff work in regulated settings. Their outputs connect directly to regulatory submissions, trial integrity, and GxP obligations.

Three problems arise that standard SOW frameworks do not resolve.

First, engagement type. Not every CRO or FSP contract fits a clean deliverables model. Some are hybrid. Some blend staff provision with milestone elements. Getting this right at the start matters. It determines whether your VMS setup, your governance model, and your bid process are fit for purpose.

Second, bid and contracting skills. Life sciences services contracts are not standard commercial deals. They carry quality obligations, regulatory scope, and audit trail needs. Building or reviewing bids in this context takes sector knowledge that most generalist teams do not have.

Third, workforce visibility. When a CRO’s team operates as part of your extended workforce, the line between services spend and workforce spend blurs. Without a single, clear view of both, you cannot manage total talent cost or plan at programme level.

Why Sector Expertise Matters, Not Just Tools

Good technology helps. A VMS with genuine SOW capability tracks milestones, manages deliverable sign-off, and gives visibility of services spend. Integration between the VMS and internal systems cuts out manual data entry. Analytics tools give procurement and HR teams a live picture of external spend.

But the tools only work when the people using them know this sector. A VMS chosen without SOW as a key criterion creates gaps. A reporting set-up built without knowledge of GxP audit needs will miss critical data. A contract structure designed by a generalist will misclassify workers and underspecify deliverables.

Life sciences SOW is not a category where good intentions bridge the gap. You need a provider who has solved these problems before.

What a Proper SOW Programme Looks Like in Life Sciences

Three things need to work together: how you design engagements, what technology you use, and how you govern commercial terms.

Engagement design means matching the contract model to the actual work. A CRO running a Phase II trial is different from an FSP providing embedded biostatistics resource. Milestones, deliverable definitions, and sign-off criteria need to reflect that. Getting this right at intake prevents misclassification and scope creep.

Technology means choosing a platform with genuine SOW capability from the start. It means building the integration layer that links that platform to internal sourcing and delivery systems. It means giving clients one clear view of services spend and supplier performance, not a picture spread across several disconnected tools.

Commercial governance means understanding how life sciences contracts work, what they need to cover, and how to benchmark rates in a market where specialist roles command premium fees.

Skills Alliance Enterprise brings deep life sciences knowledge to all three. Our VMS selection process treats SOW capability as a primary criterion. Our technology stack includes a middleware layer connecting client VMS environments to our sourcing and delivery systems. Analytics run through Microsoft Azure, giving clients a single view of total extended workforce spend across both services and contingent labour.

If your organisation manages CRO, FSP, or CDMO relationships through systems built for staff augmentation, the gap between what you spend and what you see is bigger than you think. Talk to the Skills Alliance Enterprise team to find out how a specialist approach to SOW closes that gap.

By Hodan Barltrop, Programme Director, Skills Alliance Enterprise